| Literature DB >> 19479009 |
Glinda S Cooper1, Susan L Makris, Paul J Nietert, Jennifer Jinot.
Abstract
OBJECTIVE: Our objective was to examine experimental and epidemiologic studies pertaining to immune-related, and specifically autoimmune-related, effects of trichloroethylene (TCE). DATA SOURCES AND EXTRACTION: We performed a literature search of PubMed and reviewed bibliographies in identified articles. We then systematically reviewed immune-related data, focusing on clinical and immunologic features and mechanistic studies. DATA SYNTHESIS: Studies conducted in MRL+/+ lupus mice report an accelerated autoimmune response in relation to exposure to TCE or some metabolites. Effects have been reported after 4 weeks of exposure to TCE at doses as low as 0.1 mg/kg/day in drinking water and have included increased antinuclear antibodies and interferon-gamma (IFN-gamma) and decreased secretion of interleukin-4 (IL-4), consistent with an inflammatory response. Autoimmune hepatitis, inflammatory skin lesions, and alopecia have been found after exposures of 32-48 weeks. Recent mechanistic experiments in mice examined oxidative stress and, specifically, effects on lipid-peroxidation-derived aldehydes in TCE-induced autoimmune disease. Two studies in humans reported an increase in IL-2 or IFN-gamma and a decrease in IL-4 in relation to occupational or environmental TCE exposure. Occupational exposure to TCE has also been associated with a severe, generalized hypersensitivity skin disorder accompanied by systemic effects, including hepatitis. In three case-control studies of scleroderma with a measure of occupational TCE exposure, the combined odds ratio was 2.5 [95% confidence interval (CI), 1.1-5.4] in men and 1.2 (95% CI, 0.58-2.6) in women.Entities:
Keywords: autoimmune liver disease; solvents; systemic sclerosis; trichloroethylene
Mesh:
Substances:
Year: 2009 PMID: 19479009 PMCID: PMC2685829 DOI: 10.1289/ehp.11782
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Studies of TCE and metabolite effectsa in lupus mouse strains by strain, exposure route, and duration.
| Strain, reference(s), exposure | Serology | Studies of cultured splenocytes | Clinical/histopathology results |
|---|---|---|---|
| Female MRL+/+ mice, drinking water | |||
| Increased ANA at 4 and 8 weeks; no difference between groups at 22 weeks | Increased activated CD4+ T cells and IFN-γ secretion across doses at 4 weeks, with effects reversed at 22 weeks; decreased IL-4 secretion (4 and 22 weeks) | No evidence of liver or renal damage, based on serum alanine aminotransferase, sorbitol dehydrogenase, and blood urea nitrogen | |
| Increased ANA in all treated groups at 4 weeks but not at 32 weeks | Increased activated CD4+ T cells (32 weeks) and IFN-γ secretion (4 and 32 weeks); no effect on IL-4 secretion | Extensive hepatic mononuclear cellular infiltrate in 0.5 and 2.5 mg/mL groups; hepatocyte reactive changes in all treated groups at 32 weeks | |
| Increased ANA and anti-histone antibodies at 0.9 mg/mL trichloroacetaldehyde hydrate | Increased activated CD4+ T cells at 0.1 and 0.9 g/mL doses of both metabolites; increased IFN-γ secretion at 0.9 mg/mL; no effect on IL-4 secretion | No evidence of liver or kidney damage, based on serum alanine aminotransferase and liver and kidney histology | |
| Slightly suppressed anti-ssDNA, anti-dsDNA, and anti-histone antibody expression; differences not statistically significant | Increased activated CD4+ T-cells and increased IFN-γ secretion; no effect on IL-4 secretion | Diffuse alopecia, skin inflammation and ulceration, mononuclear cell infiltration, mast cell hyperplasia, and dermal fibrosis; statistically significant increase at 0.9 mg/mL dose group but also increased at lower doses; no liver or kidney histopathology effects seen | |
| Increased ANA after 24 weeks but not statistically significant | Increased IFN-γ secretion after 36 weeks but not statistically significant | Hepatic necrosis; hepatocyte proliferation; leukocyte infiltrate in the liver, lungs, and kidneys; no difference in serum aminotransferase liver enzymes | |
| Female MRL+/+ mice, ip injection | |||
| In both groups, increased ANA and anti-ssDNA antibodies; in dichloroacetyl chloride group, anticardiolipin antibodies; no difference in anti-histone, -Sm, or -DNA antibodies | Not evaluated | Not evaluated | |
| In both treated groups, increased ANA | In both treated groups, increased IL-1α, IL-1β, IL-3, IL-6, IFN-γ, granulocyte colony–stimulating factor, and keratinocyte-derived chemokine secretion and decreased IL-5; in dichloroacetyl chloride group, increased IL-17 and IFN-α | In both treated groups, increased lymphocytes in spleen and thickening of alveolar septa with lymphocytic interstitial infiltration | |
| Female NZB × NZW mice, drinking water | |||
| Increased anti-dsDNA antibodies at some periods at ≥ 1,000 ppb | Not evaluated | At 10,000 ppb, proteinuria increased beginning at 20 weeks; renal pathology scores increased; no signs of liver disease | |
| Male MRL – | |||
| Not evaluated | Not evaluated | At ≥ 500 ppm, dose-related liver inflammation, splenomegaly, and hyperplasia of lymphatic follicles; at 1,000 ppm, immunoblastic cell formation in lymphatic follicles; no changes in thymus | |
ssDNA, single-strand DNA.
Selected end points based on those reported across most studies.
No difference reported in anti-dsDNA, anti-ss-DNA, anti-ribonucleosome, anti-SSA, anti-SSB, anti-Sm, anti-Jo-1, or anti-Scl-70 antibodies.
No difference in secretion of other cytokines measured: IL-2, IL-4, IL-10, IL-12, TNF-α, granulocyte monocyte colony–stimulating factor, macrophage inflammatory protein-1α, and RANTES (CCL-5).
Dose not given in mg/kg-day. Dose levels cited by Gilkeson et al. (2004) were incorrectly reported as 1,000 and 10,000 ppb; corrected doses (Peden-Adams MM, personal communication) are reported here.
Studies of cytokines and TCE exposure in humans.
| Reference, location, no., and age | Source of exposure data, outcome measures | Results |
|---|---|---|
| Urine sample (for trichloroacetic acid concentration); workplace TCE measures (personal samples, 4 exposed and 4 nonexposed workers); questionnaire (smoking history, age, residence); serum cytokine levels | Nonexposed workers similar to office controls for all cytokine measures; compared with nonexposed workers, TCE-exposed workers had decreased IL-4 (mean, 3.9 vs. 8.1 pg/mL), increased IL-2 (mean, 798 vs. 706 pg/mL), and increased IFN-γ (mean, 37.1 vs. 22.9 pg/mL) | |
| Indoor air sampling (child’s bedroom) of 28 volatile organic chemicals; cytokine-secreting CD3+ and CD8+ T cell populations from blood sample | TCE exposure not associated with percentages of IL-4 CD3+ or IFN-γ CD8+ T-cells | |
| Indoor air sampling (child’s bedroom) of 28 volatile organic chemicals (4 weeks after birth); cytokine-secreting CD3+ T cell populations from CD3+ cord blood cells | Increasing TCE levels associated with decreased IL-4 (OR = 4.4; 95% CI, 1.1–17.8) for < 25th percentile IL-4 and increased IFN-γ (OR = 3.6; 95% CI, 0.9–14.9) for > 75th percentile IFN-γ; no association with TNF-α or IL-2 |
Epidemiologic studies of TCE exposure and risk of scleroderma and other autoimmune diseases.
| Disease, reference, location, period, sample size, age | Source of exposure data | Exposure definition/prevalence
| |||
|---|---|---|---|---|---|
| Source of exposure data | Cohort | Cases (%) | Controls (%) | OR (95% CI) | |
| Scleroderma (systemic sclerosis) | |||||
| Structured interview (specific jobs and materials; jobs held ≥ 1 year); classified by expert review (job exposure matrix) | Men | ||||
| Any exposure | 51 | 42 | 2.0 (0.8–4.9) | ||
| Maximum intensity | 30 | 10 | 3.3 (1.0–10.3) | ||
| Cumulative intensity | 32 | 21 | 2.0 (0.7–5.3) | ||
| Maximum probability | 16 | 3 | 5.1 (NC) | ||
| Women | |||||
| Any exposure | 19 | 24 | 0.7 (0.4–1.3) | ||
| Maximum intensity | 6 | 7 | 0.9 (0.3–2.3) | ||
| Cumulative intensity | 10 | 9 | 1.2 (0.5–2.6) | ||
| Maximum probability | 4 | 5 | 0.7 (0.2–2.2) | ||
| Structured interview (specific jobs and materials; jobs held ≥ 6 months); classified by expert review | Men and women | ||||
| Any exposure | 16 | 8 | 2.4 (1.0–5.2) | ||
| High exposure | 9 | 1 | 7.6 (1.5–37.4) | ||
| Men | |||||
| Any exposure | 64 | 27 | 4.7 (0.99–21.9) | ||
| Women | |||||
| Any exposure | 9 | 4 | 2.1 (0.65–6.8) | ||
| Structured interview (specific jobs and materials; jobs held ≥ 3 months); classified by self-report and expert review | Women | ||||
| Self-report, any exposure | 1.3 | 0.7 | 2.0 (0.8–4.8) | ||
| Expert review, any exposure | 0.7 | 0.4 | 1.9 (0.6–6.6) | ||
| Undifferentiated connective tissue disease | |||||
| Structured interview (specific jobs and materials; jobs held ≥ 3 months); classified by self-report and by expert review | Women | ||||
| Self-report, any exposure | 0.5 | 0.7 | 0.88 (0.11–6.95) | ||
| Expert review, any exposure | 0.5 | 0.4 | 1.67 (0.19–14.9) | ||
| ANCA-related diseases | |||||
| Structured interview (specific jobs and materials; jobs held ≥ 6 months); classified by expert review | Men and women | ||||
| Any exposure | 18.3 | 17.5 | 1.1 (0.5 – 2.4) | ||
| Data not presented separately by sex | |||||
NC, not calculated.
The publication did not include “any” exposure, but this was generated by the original author (P. Nietert) as part of the present analysis.
Product of probability × intensity × frequency × duration scores, summed across all jobs; scores of > 1 classified as “high.”
Total number with TCE data: self-report 606 cases, 2,138 control; expert review 606 cases, 2,137 controls.
Diseases included Wegener glomerulonephritis (n = 20), microscopic polyangiitis (n = 8), pauci-immune glomerulonephritis (n = 10), uveitis (n = 6), Churg-Strauss syndrome (n = 4), stroke (n = 4), and other diseases (≤ 2 each).
Figure 1Association between risk of scleroderma and occupational exposure to TCE in men (A) and women (B), based on data from three case–control studies (Diot et al. 2002; Garabrant et al. 2003; Nietert et al. 1998). The graphics show the estimated measures of association from these studies. The pooled estimates are based on a meta-analysis using a random-effects model to include the possibility of nonrandom error between studies. Each square and corresponding line represent the OR and 95% CI from the individual study, with the relative size of the squares reflecting the relative weights of the studies. The horizontal midpoint of each diamond represents the pooled OR estimate and the horizontal extremes indicate the 95% CI.